Innocan Pharma Corporation report an additional milestone with respect to Innocan patent application: PCT application WO2021/240505 that claims Cannabinoids Based Topical Compositions for Treatment of Psoriasis of the Scalp, reached national phase. Entering the national phase is one of the major milestones in a patent lifecycle. By entering US and EU, Innocan will have the possibility to protect its pharmaceutical products in the major business countries in the world upon the patent grant.

This milestone represents the continued efforts by Innocan to provide patent protection to its products in alignment with its business goals and according to patent law requirements. Psoriasis of the scalp is a skin disorder associated with any of the following symptoms: dry scalp, scaly patches on the scalp, hair loss, burning, soreness and white scales. Scalp psoriasis may be difficult to treat and mostly it is currently being treated with intralesional steroids injected to the affected areas.

However, such treatment is typically used in small areas of the scalp. In addition, steroid use is often associated with side effects. Innocan's composition presents the potential for effective treatment without providing an unaesthetic appearance and without causing irritation to the scalp.